Kraig Biocraft Laboratories to Launch Operations at New Southeast Asia Production Facility This Week
Kraig Biocraft Laboratories (OTCQB: KBLB), a biotechnology company specializing in spider silk technology, has announced the launch of operations at its new production facility in Southeast Asia. The facility, established through a government agency collaboration, will begin its first full production cycle this week.
The site will produce the company's BAM-1 spider silk hybrid parent lines and several new transgenic strains introduced in early 2025. These next-generation strains are designed to deliver higher silk yields, improved quality, and enhanced robustness. The facility represents a strategic expansion of Kraig Labs' production capabilities as it prepares for anticipated product deliveries to potential customers.
Kraig Biocraft Laboratories (OTCQB: KBLB), una società biotecnologica specializzata nella tecnologia della seta di ragno, ha annunciato l'avvio delle operazioni nel suo nuovo stabilimento produttivo nel Sud-est asiatico. La struttura, realizzata in collaborazione con un'agenzia governativa, avvierà il primo ciclo produttivo completo questa settimana.
Il sito produrrà le linee parentali dell'ibrido di seta BAM-1 e diverse nuove varianti transgeniche introdotte all'inizio del 2025. Queste generazioni successive sono progettate per garantire rese di seta più elevate, qualità migliorata e maggiore robustezza. Lo stabilimento rappresenta un'espansione strategica della capacità produttiva di Kraig Labs in vista delle consegne previste ai potenziali clienti.
Kraig Biocraft Laboratories (OTCQB: KBLB), una empresa biotecnológica especializada en tecnología de seda de araña, anunció el inicio de operaciones en su nueva planta de producción en el sudeste asiático. La instalación, establecida en colaboración con una agencia gubernamental, comenzará su primer ciclo de producción completo esta semana.
El sitio producirá las líneas parentales del híbrido de seda BAM-1 y varias nuevas cepas transgénicas introducidas a principios de 2025. Estas cepas de nueva generación están diseñadas para ofrecer mayores rendimientos de seda, calidad mejorada y mayor robustez. La planta representa una expansión estratégica de la capacidad productiva de Kraig Labs mientras se prepara para las entregas previstas a clientes potenciales.
Kraig Biocraft Laboratories (OTCQB: KBLB)는 거미 실크 기술을 전문으로 하는 바이오테크 회사로, 동남아시아에 위치한 신규 생산 시설의 운영을 시작했다고 발표했습니다. 해당 시설은 정부 기관과의 협력으로 설립되었으며 이번 주에 첫 전체 생산 사이클을 개시합니다.
이 시설에서는 회사의 BAM-1 거미 실크 하이브리드 원계열과 2025년 초에 도입된 여러 새로운 형질전환 균주를 생산할 예정입니다. 차세대 균주들은 더 높은 실크 생산량, 향상된 품질 및 강화된 내구성을 제공하도록 설계되었습니다. 이 시설은 잠재 고객에 대한 예정된 제품 납품을 준비하는 가운데 Kraig Labs의 생산 능력을 전략적으로 확장한 것입니다.
Kraig Biocraft Laboratories (OTCQB: KBLB), une société de biotechnologie spécialisée dans la technologie de la soie d'araignée, a annoncé le lancement des opérations dans sa nouvelle unité de production en Asie du Sud-Est. L'installation, créée en collaboration avec une agence gouvernementale, entamera cette semaine son premier cycle complet de production.
Le site produira les lignées parentes de l'hybride de soie BAM-1 ainsi que plusieurs nouvelles souches transgéniques introduites début 2025. Ces souches de nouvelle génération sont conçues pour offrir des rendements de soie plus élevés, une qualité améliorée et une robustesse accrue. L'installation représente une extension stratégique des capacités de production de Kraig Labs alors que l'entreprise se prépare aux livraisons prévues auprès de clients potentiels.
Kraig Biocraft Laboratories (OTCQB: KBLB), ein Biotechnologieunternehmen, das sich auf Spinnenseidentechnologie spezialisiert hat, hat den Start der Betriebe in seiner neuen Produktionsstätte in Südostasien bekannt gegeben. Die Anlage, die in Zusammenarbeit mit einer Regierungsbehörde eingerichtet wurde, beginnt diese Woche mit dem ersten kompletten Produktionszyklus.
Am Standort werden die elterlichen Linien des BAM-1 Spinnenseiden-Hybrids sowie mehrere neue transgene Stämme produziert, die Anfang 2025 eingeführt wurden. Diese Next‑Generation-Stämme sind darauf ausgelegt, höhere Seidenausbeuten, verbesserte Qualität und erhöhte Robustheit zu liefern. Die Anlage stellt eine strategische Erweiterung der Produktionskapazitäten von Kraig Labs dar, während sich das Unternehmen auf die erwarteten Produktlieferungen an potenzielle Kunden vorbereitet.
- Strategic expansion of production capacity through new Southeast Asia facility
- Government agency collaboration providing operational security
- Introduction of new transgenic strains with improved yield and quality potential
- Enhanced production capabilities for anticipated customer deliveries
- No specific production targets or timelines provided
- Early stage of operations with unproven commercial scalability
- Dependent on successful development of new transgenic strains
New site established in collaboration with a government agency to bolster spider silk output and market readiness
ANN ARBOR, Mich., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("Company" or "Kraig Labs"), a world leader in spider silk technology*, announces that it will begin operations this week at its newest production facility. This milestone marks the launch of the first full production cycle at the site. This production site was secured earlier this summer through an agreement with a government agency in Southeast Asia.
This facility is designed to provide expanded capacity and operational security as Kraig Labs scales up its recombinant spider silk manufacturing. The site will play a key role in supporting the Company’s growth strategy as it prepares for anticipated product deliveries to potential customers and strategic markets.
This inaugural production cycle will include the rearing of the Company's parent lines for its BAM-1 spider silk hybrid, as well as several new transgenic lines that were introduced into the production environment in the first half of 2025. These next-generation strains are part of the Company’s ongoing development pipeline. These new strains are expected to complement the existing BAM-1 hybrids while delivering higher silk yields, improved silk quality, and enhanced robustness.
"This facility represents a critical step forward in our production capabilities," said Founder and CEO of Kraig Labs, Kim Thompson. "Our collaboration with government agencies in the region has created a robust platform for sustainable growth, allowing us to expand our operational footprint while maintaining close control over the quality and consistency of our spider silk."
Kraig Labs expects this production cycle to lay the groundwork for future expansion and delivery readiness of the highest-grade fibers, as it continues scaling its proprietary silk technology.
For the latest updates on Kraig Labs and its pioneering spider silk technologies, visit www.kraiglabs.com.
For details about other recent Kraig Labs advancements, please watch the Company's investor conference at www.kraiglabs.com/videos or on the Company's YouTube Channel https://www.youtube.com/@kraigbiocraftlaboratories2270.
To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news
* For a description of our historical leadership in this technology, please follow this link https://www.kraiglabs.com/world-leader/
About Kraig Biocraft Laboratories, Inc.
Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk-based fiber technologies.
The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.
Cautionary Statement Regarding Forward Looking Information
Statements in this press release about the Company's future and expectations other than historical facts are "forward-looking statements." These statements are made on the basis of management's current views and assumptions. As a result, there can be no assurance that management's expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as "believes," "plans," "expects," "anticipates," "foresees," "estimated," "hopes," "if," "develops," "researching," "research," "pilot," "potential," "could" or other words or phrases of similar import. Forward looking statements include descriptions of the Company's business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.
Ben Hansel, Hansel Capital, Inc.
(720) 288-8495
ir@KraigLabs.com
FAQ
What is the significance of Kraig Biocraft's new Southeast Asia facility?
What products will KBLB manufacture at the new facility?
When will Kraig Biocraft's new production facility begin operations?
How does this facility impact KBLB's business strategy?
What improvements are expected from KBLB's new transgenic strains?
